is the first and most advanced asset from BeiGene’s chimeric degradation activation compound (CDAC) platform. Oral presentation of the BGB-11417-101 Phase 1 study demonstrated B-cell lymphoma 2 ...

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a respiratory illness with systemic immune cell activation, inflammation, widespread multiorgan dysfunction, and thrombosis.